Matches in SemOpenAlex for { <https://semopenalex.org/work/W2022356464> ?p ?o ?g. }
- W2022356464 endingPage "620" @default.
- W2022356464 startingPage "616" @default.
- W2022356464 abstract "The ELR+ CXC chemokines are important mediators of tumorigenesis, related to their angiogenic properties. Angiogenesis appears to be a prominent feature in the progression of multiple myeloma (MM). CXC chemokines have four highly conserved cysteine amino acid residues, with the first two cysteine molecules separated by a single amino acid. The angiogenic potential of this group is determined by the presence of three amino acid residues (Glu-Leu-Arg: the ELR motif) preceding the first cysteine amino acid, in the NH2 terminus.The purpose of this study was to determine serum concentrations of angiogenesis-related chemokines ELR+ motif, such as interleukin-8 (IL-8), epithelial neutrophil activating protein-78 (ENA-78) and growth-related gene alpha (GRO-α), as well the bone marrow microvascular density (MVD) in patients with MM at diagnosis and after treatment, in plateau phase. We also evaluated the relationship among them with other known growth factors involved in angiogenesis.Serum levels of the ELR+ CXC chemokines: IL-8, ENA-78 and GRO-α as well as of the angiogenic factors: hepatocyte growth factor (HGF), vascular endothelial growth factor (VEGF) and tumor necrosis factor-α (TNF-α) were determined in 63 newly diagnosed MM patients, in 30 in plateau phase and in 20 healthy controls. Serum measurements of them were performed with commercially available kits for ELISA. Bone marrow biopsies were performed before and after treatment, in plateau phase, in order to determine MVD by staining vessels with anti-CD31.Serum concentrations of IL-8, ENA-78, GRO-α and TNF-α were significantly higher in the group of MM patients (44.5±25.3, 765±572.1, 186.5±129.1 and 4.2±2.8 pg/ml, respectively) in comparison to control group (27.3±6.4, 335.1±268.6, 112.5±76.1 and 1.3±0.8 pg/ml) (p<0.02 for GRO-α, p<0.001 for other cases). We also found that untreated patients had higher levels of IL-8, ENA-78, GRO-α than post treatment patients, but statistical significant difference was found only for IL-8 (48.36±30.93 pg/ml vs. 35.05±19.77 pg/ml, p<0.001). Furthermore IL-8, GRO-α, TNF-α, HGF and VEGF were significantly higher with increasing disease stage (p<0.001 in all cases). ENA-78 serum levels were higher in stage III than in stage I and II, but without statistical significance. Additionally we correlated each proinflammatory cytokine with well known angiogenic factors such as HGF, VEGF and TNF-α. A positive correlation was found between serum HGF and IL-8 and GRO-α (r=0.316 p<0.01, r=0.297 p<0.02, respectively). Similarly serum VEGF correlated with ENA-78 and GRO-α (r=0.323 p<0.01, r=0.469 p<0.001, respectively). In the pretreatment group of patients a positive correlation between bone marrow MVD and serum levels of GRO-α was found (r=0.304 p<0.01). There was a difference in survival times between patients with higher than median versus low IL-8, ENA-78 and GRO-α levels, but the differences could not reach statistical significance in either case.These findings support the hypothesis that ELR+ motif CXC chemokines, such as IL-8, ENA-78 and GRO-α correlate with angiogenic growth factors and may play a role in the progression of MM. Further studies are needed to determine their prognostic and predictive significance." @default.
- W2022356464 created "2016-06-24" @default.
- W2022356464 creator A5010321932 @default.
- W2022356464 creator A5012266069 @default.
- W2022356464 creator A5019577278 @default.
- W2022356464 creator A5022490857 @default.
- W2022356464 creator A5023115559 @default.
- W2022356464 creator A5035517610 @default.
- W2022356464 creator A5037393777 @default.
- W2022356464 creator A5065706324 @default.
- W2022356464 creator A5077281955 @default.
- W2022356464 creator A5089977731 @default.
- W2022356464 date "2011-12-01" @default.
- W2022356464 modified "2023-09-26" @default.
- W2022356464 title "Monitoring serum levels ELR+ CXC chemokines and the relationship between microvessel density and angiogenic growth factors in multiple myeloma" @default.
- W2022356464 cites W1569016295 @default.
- W2022356464 cites W1980312004 @default.
- W2022356464 cites W1988605844 @default.
- W2022356464 cites W1993544268 @default.
- W2022356464 cites W2000000541 @default.
- W2022356464 cites W2006382315 @default.
- W2022356464 cites W2013624045 @default.
- W2022356464 cites W2018550962 @default.
- W2022356464 cites W2029790299 @default.
- W2022356464 cites W2036831453 @default.
- W2022356464 cites W2038098798 @default.
- W2022356464 cites W2041797267 @default.
- W2022356464 cites W2053017193 @default.
- W2022356464 cites W2058301168 @default.
- W2022356464 cites W2059086521 @default.
- W2022356464 cites W2059533629 @default.
- W2022356464 cites W2061524005 @default.
- W2022356464 cites W2067545073 @default.
- W2022356464 cites W2073533090 @default.
- W2022356464 cites W2076011415 @default.
- W2022356464 cites W2079068906 @default.
- W2022356464 cites W2079555075 @default.
- W2022356464 cites W2100319157 @default.
- W2022356464 cites W2125350399 @default.
- W2022356464 cites W2132086241 @default.
- W2022356464 cites W2134055933 @default.
- W2022356464 cites W2140035585 @default.
- W2022356464 cites W2143372911 @default.
- W2022356464 cites W2143408828 @default.
- W2022356464 cites W2153372998 @default.
- W2022356464 cites W2158684700 @default.
- W2022356464 cites W2319962899 @default.
- W2022356464 cites W2471274090 @default.
- W2022356464 cites W285174310 @default.
- W2022356464 cites W2999700545 @default.
- W2022356464 doi "https://doi.org/10.1016/j.cyto.2011.08.034" @default.
- W2022356464 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21940178" @default.
- W2022356464 hasPublicationYear "2011" @default.
- W2022356464 type Work @default.
- W2022356464 sameAs 2022356464 @default.
- W2022356464 citedByCount "19" @default.
- W2022356464 countsByYear W20223564642013 @default.
- W2022356464 countsByYear W20223564642014 @default.
- W2022356464 countsByYear W20223564642015 @default.
- W2022356464 countsByYear W20223564642016 @default.
- W2022356464 countsByYear W20223564642019 @default.
- W2022356464 countsByYear W20223564642021 @default.
- W2022356464 countsByYear W20223564642023 @default.
- W2022356464 crossrefType "journal-article" @default.
- W2022356464 hasAuthorship W2022356464A5010321932 @default.
- W2022356464 hasAuthorship W2022356464A5012266069 @default.
- W2022356464 hasAuthorship W2022356464A5019577278 @default.
- W2022356464 hasAuthorship W2022356464A5022490857 @default.
- W2022356464 hasAuthorship W2022356464A5023115559 @default.
- W2022356464 hasAuthorship W2022356464A5035517610 @default.
- W2022356464 hasAuthorship W2022356464A5037393777 @default.
- W2022356464 hasAuthorship W2022356464A5065706324 @default.
- W2022356464 hasAuthorship W2022356464A5077281955 @default.
- W2022356464 hasAuthorship W2022356464A5089977731 @default.
- W2022356464 hasConcept C13373296 @default.
- W2022356464 hasConcept C167734588 @default.
- W2022356464 hasConcept C170493617 @default.
- W2022356464 hasConcept C185592680 @default.
- W2022356464 hasConcept C203014093 @default.
- W2022356464 hasConcept C2776364478 @default.
- W2022356464 hasConcept C2776914184 @default.
- W2022356464 hasConcept C2776996007 @default.
- W2022356464 hasConcept C2777025900 @default.
- W2022356464 hasConcept C2778271429 @default.
- W2022356464 hasConcept C2778690821 @default.
- W2022356464 hasConcept C2780394083 @default.
- W2022356464 hasConcept C502942594 @default.
- W2022356464 hasConcept C55493867 @default.
- W2022356464 hasConcept C68324877 @default.
- W2022356464 hasConcept C86803240 @default.
- W2022356464 hasConceptScore W2022356464C13373296 @default.
- W2022356464 hasConceptScore W2022356464C167734588 @default.
- W2022356464 hasConceptScore W2022356464C170493617 @default.
- W2022356464 hasConceptScore W2022356464C185592680 @default.
- W2022356464 hasConceptScore W2022356464C203014093 @default.
- W2022356464 hasConceptScore W2022356464C2776364478 @default.
- W2022356464 hasConceptScore W2022356464C2776914184 @default.
- W2022356464 hasConceptScore W2022356464C2776996007 @default.